BriaCell Therapeutics is developing "off-the-shelf" cellular immunotherapies designed to activate a patient’s immune system to fight cancer, a significant departure from personalized cell therapies that face cost and scaling limitations. Their lead candidate, Bria-IMT, is currently in a Phase 3 trial for metastatic breast cancer, while a new platform, Bria-OTS, allows for rapid patient matching using a saliva test to expand treatment options beyond breast cancer. The recent FDA clearance to begin a clinical trial for Bria-PROS+ in prostate cancer highlights the potential for this approach to address unmet needs in other advanced solid tumors.
Read the full article at Digital Journal
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.
